The European Commission (EC) has fined five pharmaceutical companies a total of EUR13.4 million for participating in a cartel concerning N-Butylbromide Scopolamine/Hyoscine (SNBB) – an active pharmaceutical ingredient (API)...more
10/23/2023
/ Cartels ,
Cephalon ,
Competition ,
Corporate Counsel ,
EU ,
European Commission ,
Generic Drugs ,
Life Sciences ,
Patents ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Popular ,
Prescription Drugs ,
Teva Pharmaceuticals
On 1 June 2023, the European Commission (EC) adopted revised Horizontal Block Exemption Regulations on research & development agreements (R&D BER) and specialisation agreements (Specialisation BER) (jointly referred to as...more
6/14/2023
/ Algorithms ,
Anti-Competitive ,
Competition ,
Cooperation Agreement ,
Data-Sharing ,
EU ,
European Commission ,
Exemptions ,
Horizontal Agreements ,
National Security Agency (NSA) ,
Popular ,
Sustainability ,
Treaty on the Functioning of the European Union (TFEU)
On 10 May 2022, the European Commission (EC) published the revised Vertical Block Exemption Regulation (VBER), together with the accompanying revised Guidelines on Vertical Restraints (Vertical Guidelines), which will replace...more